Progesterone Transdermal Delivery for Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular surface diseases like dry eye syndrome often cause irritation and have systemic hormone exposure concerns due to high hormone concentrations when applied topically near the eye.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of progesterone applied topically to regions outside the palpebral part of the eye, using pharmaceutically acceptable excipients to enhance penetration and minimize systemic exposure, formulated into various product types such as creams, gels, and transdermal patches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical hormone therapy is applied near the eye to treat dry eye syndrome, then treatment efficacy is improved, but eye irritation and systemic hormone exposure increase
Solution Approach 1:
The patent uses the skin of the face (forehead, temples, cheeks) as an intermediary application site that is proximate to the eye but not directly on the ocular surface. This allows hormone delivery to treat dry eye while avoiding direct contact with the sensitive eye tissues that would cause irritation, thus resolving the contradiction between efficacy and irritation.
2Reliability
If high concentrations of hormones are used in topical therapy, then treatment efficacy is improved, but systemic hormone exposure increases
Solution Approach 1:
The patent applies hormone compositions to specific localized regions of the face (forehead, temples, cheeks) rather than broadly or directly to the eye. This localized application allows concentrated hormone delivery to the target area through transdermal absorption while limiting systemic exposure by confining the application to discrete, controlled sites.
3Quantity of substance
If topical hormone composition is applied to the eye area, then tear production improves, but application safety decreases
Solution Approach 1:
Instead of applying the hormone composition directly to the eye or ocular surface as in conventional therapy, the patent inverts the approach by applying it to the surrounding facial skin areas. This reversal maintains the therapeutic benefit of increased tear production through transdermal hormone absorption while eliminating the safety risks of direct ocular application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical application of progesterone to the face outside the eye area effectively reduces dry eye symptoms without causing irritation, improving tear production and providing relief from ocular surface disorders with minimal systemic exposure.
Implementation Method 1
topical therapies comprising the application of testosterone, estrogen, and/or progesterone directly to the eye or proximately to the eye
Data Source
AI summary
The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.